Improved gene transfer selectivity to hepatocarcinoma cells by retrovirus vector displaying single-chain variable fragment antibody against c-Met.
Engineered retroviruses are widely used vectors for cancer gene therapy approaches. However, the ability to target cells of therapeutic interest while controlling the expression of the transferred genes would improve both the efficiency and the safety of viral vectors. In this study, we investigated the ability of a retroviral amphotropic envelope displaying single-chain variable-fragment (scFv) directed against the c-Met receptor, to target the entry of recombinant retroviruses to human hepatocarcinoma cells. Four single-chain antibody fragments directed against the c-Met receptor were generated and inserted into the viral envelope protein as an N-terminal fusion. The modified envelopes were incorporated into virus particles and one of the chimeric viruses, 3D6-Env, transduced preferentially human hepatoma cells rather than proliferating human hepatocytes. In another construct, the urokinase cleavage site was inserted between the scFv moiety and the envelope. Chimeric scFv-urokinase-Env viruses transduced hepatoma cells with a similar efficiency to that of the control virus and their infectivity in human hepatocytes remained low. These results indicate that amphotropic retroviruses with engineered envelopes to display scFv directed against the c-Met receptor can efficiently and selectively deliver genes into hepatoma cells.
Nguyen
Tuan Huy
TH
INSERM EMI 00-20, Hôpital A. Béclère, 157 rue de la Porte de Trivaux, 92141 Clamart, France.
Loux
Nathalie
N
Dagher
Ibrahim
I
Vons
Corinne
C
Carey
Ken
K
Briand
Pascale
P
Hadchouel
Michelle
M
Franco
Dominique
D
Jouanneau
Jacqueline
J
Schwall
Ralph
R
Weber
Anne
A
D000906:Antibodies / Q000235:genetics / Q000276:immunology; D006528:Carcinoma, Hepatocellular / Q000235:genetics* / Q000821:virology; D015870:Gene Expression; D018014:Gene Transfer Techniques; D005822:Genetic Vectors / Q000235:genetics / Q000378:metabolism; D022781:Hepatocytes / Q000502:physiology / Q000821:virology; D006801:Humans; D007135:Immunoglobulin Variable Region / Q000235:genetics*; D008113:Liver Neoplasms / Q000235:genetics*; D015202:Protein Engineering / Q000379:methods; D019859:Proto-Oncogene Proteins c-met / Q000276:immunology*; D012190:Retroviridae / Q000235:genetics / Q000472:pathogenicity; D014161:Transduction, Genetic; D014407:Tumor Cells, Cultured; D014568:Urokinase-Type Plasminogen Activator / Q000235:genetics; D014771:Virion
D000906:Antibodies; D007135:Immunoglobulin Variable Region; D019859:Proto-Oncogene Proteins c-met; D014568:Urokinase-Type Plasminogen Activator